Affiliation:
1. The author is at the Howard Hughes Medical Institute, the Department of Chemistry and Chemical Biology, and the Harvard Institute of Chemistry and Cell Biology, Harvard University, Cambridge, MA 02138, USA.
Abstract
Modern drug discovery often involves screening small molecules for their ability to bind to a preselected protein target. Target-oriented syntheses of these small molecules, individually or as collections (focused libraries), can be planned effectively with retrosynthetic analysis. Drug discovery can also involve screening small molecules for their ability to modulate a biological pathway in cells or organisms, without regard for any particular protein target. This process is likely to benefit in the future from an evolving forward analysis of synthetic pathways, used in diversity-oriented synthesis, that leads to structurally complex and diverse small molecules. One goal of diversity-oriented syntheses is to synthesize efficiently a collection of small molecules capable of perturbing any disease-related biological pathway, leading eventually to the identification of therapeutic protein targets capable of being modulated by small molecules. Several synthetic planning principles for diversity-oriented synthesis and their role in the drug discovery process are presented in this review.
Publisher
American Association for the Advancement of Science (AAAS)
Reference45 articles.
1. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide
2. Leznoff C. C., Wong J. Y., Can. J. Chem. 50, 2892 (1972).
3. Camps F., Castells J., Ferrando M. J., Font J., Tetrahedron Lett. 12, 1713 (1971).
4. Camps F., Castells J., Pi J., An. Quim. 70, 848 (1974).
5. Patchornik A., Kraus M. A., J. Am. Chem. Soc. 92, 7857 (1970).
Cited by
2380 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献